Newsfile

The newsfeed available here is provided by our content partner Newswire Corp.. It is a major and wide-reaching newswire & news provider that provides information, press releases and multimedia content for media, journalists and the general public. ActusNews enjoys a high reputation and great popularity, especially among listed companies in its home market North America.

The NewsWire Hub ("X-Billboard") currently comprises six of the most important international news sources and is supplemented by a stock market information service and additional RNS News. The individual newswire services complement each other and form a complementary information offering that covers more than three quarters of the official news sources on which editorial offices worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 63
5.905,21 S&P · 20,13 Vola-Index · 104.394,01 BTC · 1,14266 EURUSD
System-State: Number of processed items 175.780 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              

Newsfile Corp. is an important, trusted and reliable news source for private investors, investors and traders, which can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. Those who want to take a closer look at the news can access the respective news item and other analysis tools directly via the detailed views of the info cards.

NEWS
EXPLORER
CA89854F1062
State: 02.06.2025 | 6AM
Do you already know our new terminal view? Click here.
FIGI: -
TRYP
Tryp Therapeutics Inc.
GICS: - · Sector: - · Sub-Sector: -
NAME
Tryp Therapeutics Inc.
ISIN
CA89854F1062
TICKER
TRYP
MIC
XCNQ
REUTERS
TRYP.TO
BLOOMBERG
TRYP CN
Fri, 17.05.2024       Tryp Therapeutics
CA89854F1062

Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) ("Tryp" or the "Company") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the "Financial Statements"), along with the corresponding Management Discussion & Analysis (the "MD&A"). The amendmen...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 04.11.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - November 4, 2021) - - Nov. 4, 2021 - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that the Company will participate in Wonderland: Miami, presented by M...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 02.11.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - November 2, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food a...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 26.10.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - October 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company will present at the 15th Annual Pain Therapeutics Summit on November 1,...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 21.10.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - October 20, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on the Com...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 14.10.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - October 14, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its inclusion in the AdvisorShares Psychedelics ETF (the "Fund"), currently trading under the ticker symb...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 12.10.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - October 12, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the KCSA Psychedelics Virtual Investor Conference on October 14, 2021 at 3:...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 07.10.2021       Tryp Therapeutics
CA89854F1062

Tryp has partnered with Paul Hutson, PharmD and Christopher Nicholas, PhD to advance the Company's proprietary, psilocybin-based drug productSan Diego, California--(Newsfile Corp. - October 7, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Wed, 22.09.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - September 22, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Admini...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 16.09.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - September 16, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.Th...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Wed, 01.09.2021       Tryp Therapeutics
CA89854F1062

A correction from Tryp Therapeutics Inc. is being issued for the news release disseminated earlier today. The correction relates to an error in the presentation date and the disclosure of stock option grants. The presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. EDT. No other material changes were required in the bo...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Wed, 01.09.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - September 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the H.C. Wainwright Annual Global Invest...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 24.08.2021       Tryp Therapeutics
CA89854F1062

The training, conducted by Fluence, represents a best-in-class approach for psychotherapy that will accompany the administration of psilocybin for overeating disordersSan Diego, California--(Newsfile Corp. - August 24, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psil...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Wed, 18.08.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - August 18, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer, M.D., J.D., as Senior Advisor to the Company.Dr. Langer...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 10.08.2021       Tryp Therapeutics
CA89854F1062

Tryp has also entered into an agreement with Gad Consulting Services to collaborate on the preclinical studiesSan Diego, California--(Newsfile Corp. - August 10, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical ne...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Tue, 03.08.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Confer...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 29.07.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - July 28, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its interim financial results for the three and nin...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Mon, 26.07.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - July 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today the appointment of Robin Carhart-Harris, Ph.D. as Chairman of its Sc...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Wed, 21.07.2021       Tryp Therapeutics
CA89854F1062

The study is expected to be the world's first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgiaSan Diego, California--(Newsfile Corp. - July 21, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases wit...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Thu, 15.07.2021       Tryp Therapeutics
CA89854F1062

San Diego, California--(Newsfile Corp. - July 15, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will host their Q3 Investor Day on July 29, 2021 at 9:00 a.m...
Read More
Tryp Therapeutics
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the international investor community, we would like to thank Newswire Corp. for providing the news and data feeds